These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 21765981)

  • 1. Vasoactive intestinal peptide signaling axis in human leukemia.
    Dorsam GP; Benton K; Failing J; Batra S
    World J Biol Chem; 2011 Jun; 2(6):146-60. PubMed ID: 21765981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radical reversal of vasoactive intestinal peptide (VIP) receptors during early lymphopoiesis.
    Vomhof-DeKrey EE; Sandy AR; Failing JJ; Hermann RJ; Hoselton SA; Schuh JM; Weldon AJ; Payne KJ; Dorsam GP
    Peptides; 2011 Oct; 32(10):2058-66. PubMed ID: 21878358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells.
    Lara-Marquez M; O'Dorisio M; O'Dorisio T; Shah M; Karacay B
    J Immunol; 2001 Feb; 166(4):2522-30. PubMed ID: 11160313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in the relative abundance of the vasoactive intestinal peptide receptors (VPAC1 and VPAC2) and functions in uterine contractility during inflammation.
    Palus K; Całka J; Jana B
    Anim Reprod Sci; 2021 Feb; 225():106680. PubMed ID: 33388613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression.
    Delgado M; Ganea D
    J Immunol; 2000 Feb; 164(3):1200-10. PubMed ID: 10640731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
    Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
    Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
    Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA
    Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis.
    Sun W; Hong J; Zang YC; Liu X; Zhang JZ
    Int Immunol; 2006 Dec; 18(12):1691-700. PubMed ID: 17077178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide.
    Nicole P; Lins L; Rouyer-Fessard C; Drouot C; Fulcrand P; Thomas A; Couvineau A; Martinez J; Brasseur R; Laburthe M
    J Biol Chem; 2000 Aug; 275(31):24003-12. PubMed ID: 10801840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VPAC Receptor Subtypes Tune Purinergic Neuron-to-Glia Communication in the Murine Submucosal Plexus.
    Fung C; Boesmans W; Cirillo C; Foong JPP; Bornstein JC; Vanden Berghe P
    Front Cell Neurosci; 2017; 11():118. PubMed ID: 28487635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
    Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
    J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.
    Delgado M; Ganea D
    J Immunol; 2001 Jan; 166(2):1028-40. PubMed ID: 11145682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential signaling of T cell generation of IL-4 by wild-type and short-deletion variant of type 2 G protein-coupled receptor for vasoactive intestinal peptide (VPAC2).
    Huang MC; Miller AL; Wang W; Kong Y; Paul S; Goetzl EJ
    J Immunol; 2006 Jun; 176(11):6640-6. PubMed ID: 16709822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice.
    Rangon CM; Goursaud S; Medja F; Lelièvre V; Mounien L; Husson I; Brabet P; Jégou S; Janet T; Gressens P
    J Pharmacol Exp Ther; 2005 Aug; 314(2):745-52. PubMed ID: 15872042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
    Delgado M; Ganea D
    J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis.
    Yadav M; Huang MC; Goetzl EJ
    Cell Immunol; 2011; 267(2):124-32. PubMed ID: 21295288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and fine mapping of murine vasoactive intestinal peptide receptor 1.
    Karacay B; O'Dorisio MS; Kasow K; Hollenback C; Krahe R
    J Mol Neurosci; 2001 Dec; 17(3):311-24. PubMed ID: 11859927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasoactive intestinal peptide (VIP) receptor type 2 (VPAC2) is the predominant receptor expressed in human thymocytes.
    Lara-Marquez ML; O'Dorisio MS; Karacay B
    Ann N Y Acad Sci; 2000; 921():45-54. PubMed ID: 11193874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.